Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PBT2 in Early Alzheimer's Disease
NCT00471211Phase 2Completed
- Sponsor
- Alterity Therapeutics
- Start
- Dec 2006
- Primary completion
- Dec 2007
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of PBT2 in Alzheimer's disease (AD) (3 arms), sponsored by Alterity Therapeutics. Primary endpoint: Safety and Tolerability at 12 weeks. Started Dec 2006; status: completed.
02
Drugs
PBT2
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00471211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00471211.